Inactive Instrument

LABORATORIOS RICHMOND S.A.C.I.F. Share Price Buenos Aires S.E.

Equities

Pharmaceuticals

Financials

Sales 2022 1.85TCr 2.03Cr 169.58Cr Sales 2023 3.9TCr 4.29Cr 358.33Cr Capitalization 5.64TCr 6.2Cr 517.87Cr
Net income 2022 16Cr 2L 1.5Cr Net income 2023 -1.09TCr -1.19Cr -100Cr EV / Sales 2022 2.72 x
Net Debt 2022 1.89TCr 2.08Cr 173.5Cr Net Debt 2023 9.33TCr 10Cr 856.89Cr EV / Sales 2023 3.84 x
P/E ratio 2022
193 x
P/E ratio 2023
-5.2 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 17.54%
More Fundamentals * Assessed data
Dynamic Chart
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Laboratorios Richmond C I F : Argentina's Laboratorios Richmond supplies 1st batch of Russian vaccine RE
Russian Direct Investment Fund and Laboratorios Richmond Delivers the First Batch of over 1 Million Doses of the Sputnik V Vaccine Produced in Argentina to the Country's Ministry of Health CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
More news
Managers TitleAgeSince
Director/Board Member - -
Members of the board TitleAgeSince
Director/Board Member - -
Chairman - -
Director/Board Member - -
More insiders
Laboratorios Richmond SACIF is an Argentina-based company, which is engaged in the development and manufacture of pharmaceuticals. The Company's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
More about the company